Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DataMEDS AIMEDS -3.35% Return-on-Tangible-Asset is -774.98% as of Mar. 2026. The stock has 6 warning signs investors should review. Among 120 Medical Distribution companies, DataMEDS AI ranks worse than 100% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. DataMEDS AI's annualizedNet Income for the quarter that ended in Mar. 2026 was $-30.97 Mil. DataMEDS AI's average total tangible assets for the quarter that ended in Mar. 2026 was $4.00 Mil. Therefore, DataMEDS AI's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -774.98%.
The historical rank and industry rank for DataMEDS AI's Return-on-Tangible-Asset or its related term are showing as below:
MEDS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -886.47 Med: -856.8 Max: -71.84
Current: -632.08
During the past 4 years, DataMEDS AI's highest Return-on-Tangible-Asset was -71.84%. The lowest was -886.47%. And the median was -856.80%.
MEDS's Return-on-Tangible-Asset is ranked worse than 100% of 120
companies
in the Medical Distribution industry
Industry Median: 2.305
vs MEDS: -632.08
DataMEDS AI (NAS:MEDS) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
DataMEDS AI Return-on-Tangible-Asset Related Terms
DataMEDS AI Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for DataMEDS AI's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEDS vs HEWA, BLMH, PMHS: Return-on-Tangible-Asset Comparison
For the Medical Distribution subindustry, DataMEDS AI's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DataMEDS AI Return-on-Tangible-Asset vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, DataMEDS AI's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where DataMEDS AI's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -774.98% mean?
DataMEDS AI (MEDS) has a Return-on-Tangible-Asset of -774.98% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on DataMEDS AI and its competitors. According to the industry distribution chart, DataMEDS AI ranks #120 out of 120 companies in the Medical Distribution industry.
Is DataMEDS AI's Return-on-Tangible-Asset too high?
DataMEDS AI's current Return-on-Tangible-Asset is -774.98%. Based on the distribution chart, DataMEDS AI ranks #120 out of 120 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers.
How does DataMEDS AI's Return-on-Tangible-Asset compare to HEWA and BLMH?
According to the Medical Distribution industry distribution chart, DataMEDS AI ranks #120 out of 120 companies for Return-on-Tangible-Asset. This places DataMEDS AI in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Distribution company?
The median Return-on-Tangible-Asset among Medical Distribution companies is 2.31, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on DataMEDS AI and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Asset is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DataMEDS AI's current Return-on-Tangible-Asset is -774.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DataMEDS AI stock overvalued right now?
DataMEDS AI (MEDS) has a current Return-on-Tangible-Asset of -774.98%. The current Return-on-Tangible-Asset is -774.98%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For DataMEDS AI (MEDS), the current Return-on-Tangible-Asset is -774.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. The company seeks to be a micro health ecosystem, with a portfolio comprising a pharmacy, wholesale operations, and a technology division that provides a novel platform for hub and clinical services. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDS has been successfully added to your 
